Valproate synergizes with purine nucleoside analogues to induce apoptosis of B‐chronic lymphocytic leukaemia cells

Resistance to chemotherapy and drug toxicity are two major concerns of chronic lymphocytic leukaemia (B‐CLL) treatment by purine nucleoside analogues (PNA, i.e. fludarabine and cladribine). We hypothesized that targeting epigenetic changes might address these issues and evaluated the effect of the histone deacetylase inhibitor valproate (VPA) at a clinically relevant concentration. VPA acted in a highly synergistic/additive manner with fludarabine and cladribine to induce apoptosis of B‐CLL cells. Importantly, VPA also restored sensitivity to fludarabine in B cells from poor prognosis CLL patients who became resistant to chemotherapy. Mechanism of apoptosis induced by VPA alone or combined with fludarabine or to cladribine was caspase‐dependent and involved the extrinsic pathway. VPA, but neither fludarabine nor cladribine, enhanced the production of reactive oxygen species (ROS) and inhibition of ROS with N‐acetylcysteine decreases apoptosis of CLL cells. VPA stimulates hyperphosphorylation of p42/p44 ERK, cytochrome c release and overexpression of Bax and Fas. Together, our data indicate that VPA may ameliorate the outcome of PNA‐based therapeutic protocols and provide a potential alternative treatment in both the relapsed and front‐line resistant patients and in patients with high risk features.

[1]  Cheng-Chang Chang,et al.  Valproic acid resensitizes cisplatin‐resistant ovarian cancer cells , 2008, Cancer science.

[2]  M. Kohno,et al.  Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs , 2008, Cancer science.

[3]  Claudia P. Miller,et al.  Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. , 2007, Leukemia research.

[4]  H. Gronemeyer,et al.  HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. , 2007, The international journal of biochemistry & cell biology.

[5]  M. Munsell,et al.  NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. , 2007, Blood.

[6]  D. Riester,et al.  Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases , 2007, Applied Microbiology and Biotechnology.

[7]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[8]  T. Bijma,et al.  The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells , 2007, Leukemia.

[9]  Jihong Chen,et al.  Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B , 2006, Molecular Cancer.

[10]  A. Tichý,et al.  Effect of Valproic Acid, a Histone Deacetylase Inhibitor, on Cell Death and Molecular Changes Caused by Low‐Dose Irradiation , 2006, Annals of the New York Academy of Sciences.

[11]  P. Martiat,et al.  Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. , 2006, Experimental hematology.

[12]  Hsiang-Yu Lin,et al.  Targeting histone deacetylase in cancer therapy , 2006, Medicinal research reviews.

[13]  S. Johannessen,et al.  Valproate: past, present, and future. , 2006, CNS drug reviews.

[14]  K. Do,et al.  A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens , 2006, Cancer.

[15]  P. Atadja,et al.  The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. , 2006, Molecular pharmacology.

[16]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[17]  F. Bontemps,et al.  Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). , 2005, International journal of oncology.

[18]  A. Burny,et al.  Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Do,et al.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Payne,et al.  Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. , 2005, Cancer research.

[22]  O. Bosco,et al.  Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[24]  S. Pileri,et al.  Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Grever,et al.  The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.

[26]  D. Paik,et al.  The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells , 2004, Cancer Research.

[27]  R. Blaheta,et al.  Valproate and valproate-analogues: potent tools to fight against cancer. , 2002, Current medicinal chemistry.

[28]  P. Zinzani.  A Randomized Trial of Fludarabine and Mitoxantrone Plus Rituximab vs CHOP Plus Rituximab as First-Line Treatment in Patients With Follicular Lymphoma , 2002 .

[29]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[30]  Seamus J. Martin,et al.  Apoptosis‐associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl‐2 , 2001, The EMBO journal.

[31]  A. Anel,et al.  Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. , 2001, The Biochemical journal.

[32]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Kantarjian,et al.  Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Rose,et al.  Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. , 2000, Blood.

[35]  S. Kaufmann,et al.  Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  B. Freidlin,et al.  Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Y. Hsu,et al.  Conformation of the Bax C‐terminus regulates subcellular location and cell death , 1999, The EMBO journal.

[38]  M. Błasińska-Morawiec,et al.  2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger , 1999, Leukemia.

[39]  E. Anaissie,et al.  Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine , 1998, Annals of Internal Medicine.

[40]  E J Freireich,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.

[41]  H. Doerr,et al.  Antitumor activity of sodium valproate in cultures of human neuroblastoma cells , 1996, Anti-cancer drugs.

[42]  Tallman,et al.  Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders [published erratum appears in Blood 1996 Mar 1;87(5):2093] , 1995 .

[43]  B. Cheson.  Infectious and immunosuppressive complications of purine analog therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[45]  E. Estey,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.

[46]  J. Simiand,et al.  Mechanism of anticonvulsant action of valproate , 1982, Progress in Neurobiology.

[47]  M. Bialer,et al.  Valproic acid: Second generation , 2011, Neurotherapeutics.

[48]  U. Mahlknecht,et al.  Valproic Acid Sensitizes Chronic Lymphocytic Leukemia Cells to Apoptosis and Restores the Balance Between Pro- and Antiapoptotic Proteins , 2008, Molecular medicine.

[49]  Z. Kostrouch,et al.  Valproic acid, a molecular lead to multiple regulatory pathways. , 2007, Folia biologica.

[50]  J. Byrd,et al.  Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. , 2005, Blood.

[51]  Lucia Altucci,et al.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[52]  E. Montserrat.  Treatment options in chronic lymphocytic leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.

[53]  R. Blaheta,et al.  Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. , 2002, International journal of oncology.

[54]  Yahong Lin,et al.  TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. , 2002, Genes & development.

[55]  A. Kasprzyk,et al.  Myelodysplasia Following Treatment of Chronic Lymphocytic Leukaemia with Fludarabine. , 1999, Hematology.

[56]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[57]  M. Tallman,et al.  Myelodysplastic following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA) , 1997, Leukemia.

[58]  S. Kroft,et al.  Plasmacytoid leukemia of chinook salmon , 1997 .

[59]  M. Tallman,et al.  Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. , 1995, Blood.

[60]  M. Talpaz,et al.  Fludarabine therapy in chronic lymphocytic leukemia (CLL). , 1988, Nouvelle revue francaise d'hematologie.